Streetbeat News

Price Targets

NET

Cloudflare's stock is trading higher following Baird's decision to maintain an Outperform rating on the stock and increase its price target from $59 to $64.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 3:24 pm

BMY

Over the past 3 months, 4 analysts have published their opinion on Bristol-Myers Squibb (NYSE:BMY) stock. The company has an average price target of $76.5 with a high of $85.00 and a low of $65.00. This average price target has increased by 1.55% over the past month.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 3:01 pm

KFY

Truist Securities analyst Tobey Sommer has reiterated a 'Buy' rating on Korn Ferry (NYSE:KFY) and maintained a price target of $25.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 2:58 pm

EWTX

Truist Securities analyst Srikripa Devarakonda has reiterated a 'Buy' rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 2:57 pm

BMY

Truist Securities analyst Gregg Gilbert has reiterated a 'Buy' rating on Bristol-Myers Squibb (NYSE:BMY) and maintained an $84 price target.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 2:56 pm

SITC

Truist Securities analyst Ki Bin Kim has reiterated a 'Hold' rating on SITE Centers (NYSE:SITC) and maintained a price target of $14.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 2:55 pm

RYN

Truist Securities analyst Michael Roxland has reiterated a 'Hold' rating on Rayonier (NYSE:RYN) and maintained a price target of $33.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 2:54 pm

PSTL

Truist Securities analyst Ki Bin Kim has reiterated a 'Hold' rating on Postal Realty Trust (NYSE:PSTL) and maintained a price target of $16.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 2:54 pm

LNTH

Truist Securities analyst Richard Newitter has reiterated a 'Buy' rating on Lantheus Holdings (NASDAQ:LNTH) and maintained a price target of $125.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 2:51 pm

CHRS

Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Coherus BioSciences (NASDAQ:CHRS) and maintained a price target of $22.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 2:49 pm